<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Han JW</submitter><funding>Ministry of Science and ICT</funding><funding>National Research Foundation of Korea</funding><pagination>219-231</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9013623</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>28(2)</volume><pubmed_abstract>&lt;h4>Background/aims&lt;/h4>Sarcopenia is an independent prognostic factor of liver cirrhosis (LC). However, the association between LC-related systemic inflammation and sarcopenia is unclear.&lt;h4>Methods&lt;/h4>Sprague-Dawley rats were treated with thioacetamide (TAA) or saline as a control. Rifaximin was administered to TAA-induced LC rats. Enzyme-linked immunosorbent assay was performed to measure inflammatory mediators in rat serum. RT-PCR was performed to measure the molecular expression in tissues. Hematoxylin and eosin (H&amp;E) staining and immunohistochemistry were performed to investigate tissue pathology. Serum tumor necrosis factor-α levels, liver stiffness (LS), and the L3 skeletal muscle index (L3SMI) were measured in 60 patients with chronic liver disease.&lt;h4>Results&lt;/h4>LC and sarcopen</pubmed_abstract><journal>Clinical and molecular hepatology</journal><pubmed_title>Association between serum tumor necrosis factor-α and sarcopenia in liver cirrhosis.</pubmed_title><pmcid>PMC9013623</pmcid><funding_grant_id>2017R1C1B5076061</funding_grant_id><pubmed_authors>Kim DI</pubmed_authors><pubmed_authors>Nam HC</pubmed_authors><pubmed_authors>Chang UI</pubmed_authors><pubmed_authors>Song DS</pubmed_authors><pubmed_authors>Yang JM</pubmed_authors><pubmed_authors>Han JW</pubmed_authors></additional><is_claimable>false</is_claimable><name>Association between serum tumor necrosis factor-α and sarcopenia in liver cirrhosis.</name><description>&lt;h4>Background/aims&lt;/h4>Sarcopenia is an independent prognostic factor of liver cirrhosis (LC). However, the association between LC-related systemic inflammation and sarcopenia is unclear.&lt;h4>Methods&lt;/h4>Sprague-Dawley rats were treated with thioacetamide (TAA) or saline as a control. Rifaximin was administered to TAA-induced LC rats. Enzyme-linked immunosorbent assay was performed to measure inflammatory mediators in rat serum. RT-PCR was performed to measure the molecular expression in tissues. Hematoxylin and eosin (H&amp;E) staining and immunohistochemistry were performed to investigate tissue pathology. Serum tumor necrosis factor-α levels, liver stiffness (LS), and the L3 skeletal muscle index (L3SMI) were measured in 60 patients with chronic liver disease.&lt;h4>Results&lt;/h4>LC and sarcopen</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Apr</publication><modification>2025-04-22T01:44:31.489Z</modification><creation>2025-04-05T20:05:12.671Z</creation></dates><accession>S-EPMC9013623</accession><cross_references><pubmed>34281295</pubmed><doi>10.3350/cmh.2021.0082</doi></cross_references></HashMap>